Jules Levin at NATAP has provided this awesome summary of the presentations from the combined AASLD/EASL HCV elimination conference. The first one starts with the elephant in the room, namely the prices… The Cost of HCV Elimination – AASLD-EASL HCV Special Conference Miami 2/1/19 – (02/04/19) Is There a Need to Re-Focus our Efforts for […]
Category Archives: Blogs
Welcome to FixHepC, a trusted resource for those seeking effective and affordable solutions for Hepatitis C treatment. Our mission is to empower individuals with the knowledge and access to life-saving medications, ensuring that everyone has the opportunity to cure this condition. With expert guidance, patient testimonials, and up-to-date information on the latest treatments, we are here to support your journey toward a Hepatitis C-free life. Explore our resources, learn more about your treatment options, and take the first step toward a healthier future.
Our blog at FixHepC is dedicated to providing valuable insights, updates, and support for those affected by Hepatitis C. Here, you’ll find a wide range of topics, including the latest breakthroughs in Hepatitis C treatments, expert tips on managing the condition, and personal stories from individuals who have successfully undergone treatment. We also cover important health news, information on accessing affordable medications, and advice on navigating the healthcare system. Whether you’re newly diagnosed or exploring treatment options, our blog offers clear, reliable, and compassionate information to help you make informed decisions about your health.
24
Jan
Jan
When sofosbuvir first reached the market it was not approved for patients with CKD (Chronic Kidney Disease) stages 4 and 5 which means patients with an eGFR of < 30 ml/min. This was based on the observations that: Sofosbuvir is rapidly metabolised to GS-331007 (t1/2 0.4 hours), and GS-331007 (t1/2 27 hours) has renal excretion, […]
18
Jan
Jan
Perhaps it’s age, perhaps it’s Hep C, perhaps it’s the medication. Whatever the reason, the reality is quite a few people with Hep C have issues with tinnitus. A friend of mine called Davo had this issue and resorted to Google where he found an Australian company called “Sound Therapy International”. Lucky it was him, rather […]
05
Jan
Jan
It’s come to my attention that some people on the Internet are “bad-mouthing” Maviret (Mavyret) and suggesting it’s the worst option on the market and that you need Sofosbuvir. Anyone stating this does not, as they say, know their ass from their elbow – this drug is awesome where awesome means great cure rates, short […]
27
Dec
Dec
For the past 2 decades, Jules Levin at NATAP has done a fantastic job reporting what is presented at all the major scientific meetings on HIV, HBV and HCV around the world. Here are 83 studies presented at the AASLD 2018 conference that cover the leading edge of Hep C research as it currently stands. Hepatitis Debrief: […]
17
Dec
Dec
In an announcement worthy of 3 dancing bananas , PHARMAC in New Zealand have just announced: We are pleased to announce a decision to fund a new treatment for chronic hepatitis C infection, glecaprevir and pibrentasvir (Maviret) from 1 February 2019, and to widen access to adalimumab (Humira) for patients with psoriasis from 1 July 2019, […]
10
Dec
Dec
Here is a summary slide set where expert faculty members summarize key viral hepatitis studies from AASLD 2018 in San Francisco. Use these slides to review data on newer HCV regimens, the HCV continuum of care, posttreatment HCV outcomes, HCV D+R- transplantation, NA cessation in chronic hepatitis B, and investigational HBV/HDV therapeutics. Clinical Impact of […]
27
Nov
Nov
The usual way we detect Hepatitis C is using an Antibody test. Following infection with Hepatitis C the body forms antibodies to the virus and these antibodies persist lifelong. In about 25% of patients the antibodies successfully remove the virus, however, the remaining 75% of patients go on to develop chronic Hepatitis C (persistent infection). […]
12
Nov
Nov
The Medicines Patent Pool Signs Licence with AbbVie to Expand Access to Key Hepatitis C Treatment, Glecaprevir/Pibrentasvir SAN FRANCISCO, November 12, 2018 /PRNewswire/ — Important collaboration will ensure affordable hepatitis C treatment options in low- and middle-income countries. The Medicines Patent Pool (MPP) has today announced a new, royalty-free licence agreement with AbbVie for glecaprevir/pibrentasvir (G/P) – a World Health […]
08
Nov
Nov
One of the feared complications of Hepatitis C is HepatoCellular Carcinoma (HCC) aka Liver Cancer. While anyone can get this type of cancer it is most common in patients who have liver cirrhosis from any cause. We look for it using a blood test for AlphaFeto Protein (AFP) and/or Ultrasound, CT or MRI. Ok, so the […]